A Phase 2 interventional study of GS-248 and Placebo in Systemic Sclerosis, sponsored by Gesynta Pharma AB. Completed at 12 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-08-09.
Sponsored by Gesynta Pharma AB · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Scleroderma, Systemic with a site in United Kingdom — 10 open to participants now, 14 under way, 5 of them phase 3. Scleroderma, Systemic · United Kingdom.
Among the 56 studies in Scleroderma, Systemic with a site in United Kingdom, this one is the 16th largest by enrollment of the 44 interventional ones that give a count, is one of 3 that started in 2020, is one of 27 in phase 2, and was the 35th registered.
613 studies on the registry are indexed under Scleroderma, Systemic; 221 are open to participants now.
Browse Scleroderma, Systemic studies →10 of the 56 studies in Scleroderma, Systemic with a site in United Kingdom are open now. Recruiting first, the newest first:
AstraZeneca · Sites in United Kingdom, United States, Argentina and 32 more countries
Ages 5–80
Boehringer Ingelheim · Sites in United Kingdom, United States, Argentina and 42 more countries
Ages 18+
Quell Therapeutics Limited · Sites in United Kingdom, Germany, Spain
Ages 18+
AstraZeneca · Sites in United Kingdom, United States, Australia and 3 more countries
Ages 18–75
Relation Therapeutics · Sites in United Kingdom
Ages 18+ · Healthy volunteers
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 145 Scleroderma, Systemic studies recruiting now, 83 (57%) set no upper age limit and 49 (34%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 30 · Phase 3 8 · Phase 4 1
First in 2007; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 94 is above the median of 37 across 449 interventional studies indexed under Scleroderma, Systemic.
Median enrollment 58 across the 44 interventional studies, 495 across the 12 observational. Of the 34 that completed or were terminated, 18 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 56 have an industry lead sponsor. The 10 most frequent:
Gesynta Pharma AB is the lead sponsor of 4 studies on the registry; none are open to participants now.
Gesynta Pharma AB has 1 study filed under Scleroderma, Systemic — fewer than ten, so there is no comparison to draw.
5 of the studies in Scleroderma, Systemic with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT06655155argenxA Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis | 2027-03 |
| NCT06843239Zura Bio IncTibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE) | 2027-05 |
| NCT06308978Fate TherapeuticsA Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease | 2027-09-30 |
| NCT06894654Relation TherapeuticsDERMATOMICS: Identifying Regulators of Skin Homeostasis | 2027-11-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 56 studies in Scleroderma, Systemic with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to determine the safety, and evaluate the efficacy of GS-248 versus placebo on Raynaud's Phenomenon (RP) in subjects with Systemic Sclerosis (SSc).
The primary objective of this study is to determine the safety, and evaluate the efficacy of GS-248 versus placebo on Raynaud's Phenomenon (RP) in subjects with Systemic Sclerosis (SSc).
This is a randomized, double-blind, placebo-controlled study conducted in multiple sites in 4 countries in Europe. Approximately 80 subjects will be randomized in a 1:1 allocation to receive either GS-248 (120 mg) or placebo once daily. The study will comprise an enrolment period, a treatment period, and a follow-up period, with a total of 5 study visits over approximately 10 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GS-248, capsule, 120 mg, once daily for 4 weeks
Drug: GS-248
placebo, capsule, once daily for 4 weeks
Drug: Placebo
120 mg, capsule, once daily for 4 weeks
capsule, once daily for 4 weeks
Mean Change From Baseline to Week 4 in the Number of Raynaud Attacks Per Week.
Patient reported number of Raynaud's attacks per day as registered in electronic diary.
Time frame: From baseline to week 4, i.e. the 7 most recent days prior to Visit 2 and Visit 4 respectively
Mean Change From Baseline to Week 4 in the Raynaud's Condition Score.
Patients reported Raynaud's Condition Score (RCS) once a day in an electronic diary. RCS is a validated numeric rating scale (from 0 to 10) answering the question "What difficulty did you have today with your Raynaud's condition?" where a score of '0' = 'No difficulty', and a score of '10' = 'Extreme difficulty'.
Time frame: From baseline to week 4, i.e. the 7 most recent days prior to Visit 2 and Visit 4 respectively
Mean Change From Baseline to Week 4 in Pain Experienced During Raynaud Attacks.
The patient reported the experienced pain of each Raynaud attack using a Numeric Rating Scale (NRS) from 0 to 10 in an electronic diary where '0'='No pain' and '10'='Worst imaginable pain'.
Time frame: From baseline to week 4, i.e. the 7 most recent days prior to Visit 2 and Visit 4 respectively
Mean Change From Baseline to Week 4 in the Mean Duration of Raynaud's Attacks
The patient reported the start time (hh:mm) and stop time (hh:mm) of each Raynaud's attack in the electronic diary.
Time frame: From baseline to week 4, i.e. the 7 most recent days prior to Visit 2 and Visit 4 respectively
Mean Change From Baseline to Week 4 in the Cumulative Duration of Raynaud Attacks.
The patient reported the start time (hh:mm) and stop time (hh:mm) of each Raynaud's attack in the electronic diary.
Time frame: From baseline to week 4, i.e. the 7 most recent days prior to Visit 2 and Visit 4 respectively
In addition to fulfilling all eligibility criteria, subjects must fulfil the following criteria to be randomised: •≥7 RP attacks during the last week of the run-in period as captured in the eDiary, with no more than 2 days without RP attacks. •Compliance with the eDiary during the 7 most recent days prior to baseline (Visit 2), excluding the visit day itself, defined as having submitted ≥5 days of eDiary records (out of a possible 7 days) for RCS and RP during that period.
| Milestone | GS-248 | Placebo |
|---|---|---|
| Started | 33 | 36 |
| Completed | 30 | 34 |
| Not completed | 3 | 2 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Adverse event | 1 | 2 |
| Milestone | GS-248 | Placebo |
|---|---|---|
| Started | 30 | 34 |
| Completed | 30 | 34 |
| Not completed | 0 | 0 |
Patient reported number of Raynaud's attacks per day as registered in electronic diary.
| number of attacks | GS-248 | Placebo |
|---|---|---|
| Mean Change From Baseline to Week 4 in the Number of Raynaud Attacks Per Week. | -3.41 (-5.83 to -0.99) | -4.22 (-6.48 to -1.96) |
Patients reported Raynaud's Condition Score (RCS) once a day in an electronic diary. RCS is a validated numeric rating scale (from 0 to 10) answering the question "What difficulty did you have today with your Raynaud's condition?" where a score of '0' = 'No difficulty', and a score of '10' = 'Extreme difficulty'.
| score | GS-248 | Placebo |
|---|---|---|
| Mean Change From Baseline to Week 4 in the Raynaud's Condition Score. | -0.99 (-1.54 to -0.45) | -0.95 (-1.45 to -0.46) |
The patient reported the experienced pain of each Raynaud attack using a Numeric Rating Scale (NRS) from 0 to 10 in an electronic diary where '0'='No pain' and '10'='Worst imaginable pain'.
| numeric rating scale | GS-248 | Placebo |
|---|---|---|
| Mean Change From Baseline to Week 4 in Pain Experienced During Raynaud Attacks. | -0.65 (-1.16 to -0.14) | -0.60 (-1.07 to -0.13) |
The patient reported the start time (hh:mm) and stop time (hh:mm) of each Raynaud's attack in the electronic diary.
| LN (minutes); back-transformed | GS-248 | Placebo |
|---|---|---|
| Mean Change From Baseline to Week 4 in the Mean Duration of Raynaud's Attacks | 1.06 (0.87 to 1.29) | 0.89 (0.74 to 1.08) |
The patient reported the start time (hh:mm) and stop time (hh:mm) of each Raynaud's attack in the electronic diary.
| LN (minutes); back-transformed | GS-248 | Placebo |
|---|---|---|
| Mean Change From Baseline to Week 4 in the Cumulative Duration of Raynaud Attacks. | 0.70 (0.51 to 0.98) | 0.61 (0.45 to 0.82) |
Collected over All AEs and SAEs were collected during the full study period from the signing of the ICF until the last study visit (2-3 weeks run-in period, 4 weeks treatment period and 2-3 weeks follow-up period; i.e. 8-10 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GS-248 | 0/33 (0%) | 0/33 (0%) | 10/33 (30.3%) |
| Placebo | 1/36 (2.8%) | 1/36 (2.8%) | 9/36 (25%) |
| Event | GS-248 | Placebo |
|---|---|---|
| Thermal burnInjury, poisoning and procedural complications | 0/33 | 1/36 |
| SepsisInfections and infestations | 0/33 | 1/36 |
| Event | GS-248 | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 6/33 | 4/36 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/33 | 3/36 |
| Abdominal pain upperGastrointestinal disorders | 2/33 | 0/36 |
| NauseaGastrointestinal disorders | 2/33 | 1/36 |
| White blood cell count decreasedInvestigations | 0/33 | 2/36 |
| Age, Categorical(Participants) | GS-248 | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 30 | 32 | 62 |
| >=65 years | 3 | 4 | 7 |
| Age, Continuous(years) | GS-248 | Placebo | Total |
|---|---|---|---|
| Mean | 49.0 ± 10.6 | 50.6 ± 10.6 | 49.8 ± 10.5 |
| Sex: Female, Male(Participants) | GS-248 | Placebo | Total |
|---|---|---|---|
| Female | 27 | 33 | 60 |
| Male | 6 | 3 | 9 |
| Race (NIH/OMB)(Participants) | GS-248 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 30 | 34 | 64 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 2 | 4 |
| Region of Enrollment(participants) | GS-248 | Placebo | Total |
|---|---|---|---|
| Netherlands | 2 | 3 | 5 |
| Belgium | 2 | 1 | 3 |
| Poland | 17 | 20 | 37 |
| United Kingdom | 12 | 12 | 24 |
| Stratification factors FAS(Participants) | GS-248 | Placebo | Total |
|---|---|---|---|
| Ca-blockers | 18 | 19 | 37 |
| PDE-5 inhibitors | 9 | 10 | 19 |
| No treatment | 6 | 7 | 13 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2020 to primary completion in Jun 2022, 17 months.
Results were first posted in Aug 2024, 2 years 1 month after primary completion.
Of 48 phase 2 interventional studies under Scleroderma, Systemic, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 83. This study's 17 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vipoglanstat
Gesynta Pharma AB